Search
Search Results
-
Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)
BackgroundAdvanced pancreatic cancer is one of the leading causes of cancer-related deaths. For patients with advanced pancreatic cancer, gemcitabine...
-
Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study
BackgroundAlthough pancreatic ductal adenocarcinoma (PDAC) rarely metastasizes to the skeleton, disseminated tumor cells have been detected in bone...
-
Human Microbiome Modulation: A Potential Therapeutic Strategy for Pancreatic Cancer
Pancreatic cancer is a disorder that affects the biochemical and metabolic physiology of pancreas. It is the most intractable and lethal of all GI...
-
The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study
IntroductionCONTACT is a national multidisciplinary study assessing the impact of the COVID-19 pandemic upon diagnostic and treatment pathways among...
-
Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with poor prognosis
BackgroundRecent studies using single-cell transcriptomic analysis have reported several distinct clusters of neoplastic epithelial cells and...
-
Searching for novel multimodal treatments in oligometastatic pancreatic cancer
BackgroundMetastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients...
-
Landmarks in pancreatic cancer studies
Pancreatic cancer is a rare but fatal disease. Patients present advanced disease due to the lack of or typical symptoms when the tumor is still...
-
Precision oncology for intrahepatic cholangiocarcinoma in clinical practice
BackgroundAdvanced cholangiocarcinoma has a poor prognosis. Molecular targeted approaches have been proposed for patients after progression under...
-
Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment
As a significant contributor to cancer-related death, pancreatic cancer, as a recalcitrant tumor, generally has an appalling prognosis that has not...
-
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
BackgroundNanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/ levo -leucovorin ( Levo -LV) was approved for unresectable pancreatic cancer...
-
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial
BackgroundSurgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard...
-
A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma
BackgroundThere are no standard third-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC). Trametinib in combination with...
-
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients...
-
Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and poor survival. We studied 83 spatial samples from 31 patients...
-
Immunotherapy for Pancreatic Cancer
Pancreatic cancer is currently the fourth leading cause of cancer-related deaths with a high fatality rate, and is predicted to become the second...
-
The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer
The Spanish Familial Pancreatic Cancer Registry (PANGENFAM) was established in 2009 and aims to characterize the genotype and phenotype of familial...
-
Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study
BackgroundPeriampullary cancer is a term for cancers arising in or in close proximity to the pancreas. Pancreatic cancer is the 3 rd leading cause of...
-
Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery
BackgroundWith the advent of intensive combination regimens, an increasing number of patients with unresectable pancreatic cancer (UPC) have regained...
-
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
BackgroundAccording to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall...
-
Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma
BackgroundSystemic inflammatory scores may aid prognostication and patient selection for trials. We compared five scores in advanced pancreatic...
